did-you-know? rent-now

Amazon no longer offers textbook rentals. We do!

did-you-know? rent-now

Amazon no longer offers textbook rentals. We do!

We're the #1 textbook rental company. Let us show you why.

9780471254010

Principles of Psychopharmacology for Mental Health Professionals

by ; ;
  • ISBN13:

    9780471254010

  • ISBN10:

    0471254010

  • Edition: 1st
  • Format: Paperback
  • Copyright: 2006-06-23
  • Publisher: Wiley-Liss
  • Purchase Benefits
  • Free Shipping Icon Free Shipping On Orders Over $35!
    Your order must be $35 or more to qualify for free economy shipping. Bulk sales, PO's, Marketplace items, eBooks and apparel do not qualify for this offer.
  • eCampus.com Logo Get Rewarded for Ordering Your Textbooks! Enroll Now
  • Write a Review Icon Write a Review
List Price: $146.08 Save up to $0.73
  • Buy New
    $145.35
    Add to Cart Free Shipping Icon Free Shipping

    PRINT ON DEMAND: 2-4 WEEKS. THIS ITEM CANNOT BE CANCELLED OR RETURNED.

Supplemental Materials

What is included with this book?

Summary

Principles of Psychopharmacology for Mental Health Professionals addresses the current "split" model of mental health care, in which physicians provide pharmaco-therapy while non-prescribing practitioners oversee other services such as psychotherapy. Bringing these two areas together, this book familiarizes mental health professionals with the medications used to treat psychiatric disorders.

Author Biography

Jeffrey E. Kelsey is the author of Principles of Psychopharmacology for Mental Health Professionals, published by Wiley.

Charles Barnet Nemeroff is an American psychiatrist known for his work in treating depression. He is the author of numerous textbooks, papers, and clinical studies.

D. Jeffrey Newport is the author of Principles of Psychopharmacology for Mental Health Professionals, published by Wiley.

Table of Contents

Preface xv
Faculty Disclosure xvii
1 INTRODUCTION AND OVERVIEW
1(8)
Additional Reading
7(2)
2 BASICS OF PSYCHOPHARMACOLOGY
9(28)
2.1 Introduction
9(1)
2.1.1 Learning the Language of Pharmacology
9(1)
2.1.2 Overview
10(1)
2.2 Normal Human Nervous System
10(9)
2.2.1 Neuroanatomy: Structure of the Nervous System
11(3)
2.2.2 Neurophysiology: Function of the Nervous System
14(5)
2.3 Pathophysiology: Study of What Goes Wrong
19(3)
2.3.1 What Goes Wrong
20(1)
2.3.2 Why It Goes Wrong
21(1)
2.4 Pharmacology
22(10)
2.4.1 Introduction
22(1)
2.4.2 Pharmacokinetics
23(3)
2.4.3 Pharmacodynamics
26(3)
2.4.4 Predicting Medication Effects
29(1)
2.4.5 Predicting Drug Interactions
30(2)
2.5 Putting It All Together
32(2)
Additional Reading
34(3)
3 MOOD DISORDERS
37(60)
3.1 Introduction
37(2)
3.2 Major Depressive Disorder
39(29)
3.2.1 Brief Description and Diagnostic Criteria
39(1)
3.2.2 Prevalence and Risk Factors
40(1)
3.2.3 Presentation and Clinical Course
41(1)
3.2.4 Initial Evaluation and Differential Diagnosis
42(4)
3.2.5 History of Pharmacological Treatment
46(14)
3.2.6 Current Approach to Treatment
60(6)
3.2.7 Refractory Depression
66(2)
3.3 Dysthymic Disorder
68(3)
3.3.1 Brief Description and Diagnostic Criteria
68(1)
3.3.2 Prevalence and Risk Factors
68(1)
3.3.3 Presentation and Clinical Course
68(1)
3.3.4 Initial Evaluation and Differential Diagnosis
69(1)
3.3.5 History of Pharmacological Treatment
69(1)
3.3.6 Current Approach to Treatment
70(1)
3.3.7 Refractory Depression
70(1)
3.4 Bipolar Disorders
71(23)
3.4.1 Brief Description and Diagnostic Criteria
71(2)
3.4.2 Prevalence and Risk Factors
73(1)
3.4.3 Presentation and Clinical Course
73(1)
3.4.4 Initial Evaluation and Differential Diagnosis
74(4)
3.4.5 History of Pharmacological Treatment
78(9)
3.4.6 Current Approach to Treatment
87(7)
Additional Reading
94(3)
4 SCHIZOPHRENIA
97(30)
4.1 Brief Description and Diagnostic Criteria
97(3)
4.2 Prevalence and Risk Factors
100(1)
4.3 Presentation and Clinical Course
100(2)
4.4 Initial Evaluation and Differential Diagnosis
102(5)
4.5 History of Treatment
107(13)
4.6 Current Approach to Treatment
120(4)
4.6.1 Prodromal Phase
120(1)
4.6.2 Acute Phase
121(2)
4.6.3 Maintenance Phase
123(1)
4.6.4 Residual Phase
124(1)
4.7 Treatment Resistant Schizophrenia
124(1)
Additional Reading
125(2)
5 ANXIETY DISORDERS
127(50)
5.1 Introduction
127(9)
5.1.1 History of Anxiety Disorders
127(1)
5.1.2 Anxiety Symptoms
128(1)
5.1.3 Brief Overview of the Anxiety Disorders
129(1)
5.1.4 History of Pharmacological Treatment for Anxiety
130(6)
5.2 Panic Disorder
136(9)
5.2.1 Brief Description and Diagnostic Criteria
136(2)
5.2.2 Prevalence and Risk Factors
138(1)
5.2.3 Presentation and Clinical Course
138(1)
5.2.4 Initial Evaluation and Differential Diagnosis
139(2)
5.2.5 History of Pharmacological Treatment
141(2)
5.2.6 Current Approach to Treatment
143(2)
5.3 Generalized Anxiety Disorder
145(7)
5.3.1 Brief Description and Diagnostic Criteria
145(1)
5.3.2 Prevalence and Risk Factors
145(1)
5.3.3 Presentation and Clinical Course
146(1)
5.3.4 Initial Evaluation and Differential Diagnosis
146(2)
5.3.5 History of Pharmacological Treatment
148(3)
5.3.6 Current Approach of Treatment
151(1)
5.4 Obsessive–Compulsive Disorder
152(7)
5.4.1 Brief Description and Diagnostic Criteria
152(1)
5.4.2 Prevalence and Risk Factors
153(1)
5.4.3 Presentation and Clinical Course
154(1)
5.4.4 Initial Evaluation and Differential Diagnosis
155(1)
5.4.5 History of Pharmacological Treatment
156(2)
5.4.6 Current Approach to Treatment
158(1)
5.5 Social Anxiety Disorder (Social Phobia)
159(8)
5.5.1 Brief Description and Diagnostic Criteria
159(1)
5.5.2 Prevalence and Risk Factors
160(1)
5.5.3 Presentation and Clinical Course
160(1)
5.5.4 Initial Evaluation and Differential Diagnosis
161(1)
5.5.5 History of Pharmacological Treatment
162(4)
5.5.6 Current Approach to Treatment
166(1)
5.6 Post-Traumatic Stress Disorder
167(8)
5.6.1 Brief Description and Diagnostic Criteria
167(1)
5.6.2 Prevalence and Risk Factors
168(1)
5.6.3 Presentation and Clinical Course
169(1)
5.6.4 Initial Evaluation and Differential Diagnosis
170(1)
5.6.5 History of Pharmacological Treatment
171(3)
5.6.6 Current Approach to Treatment
174(1)
Additional Reading
175(2)
6 SUBSTANCE USE DISORDERS
177(30)
6.1 Introduction
177(3)
6.1.1 The Illness Model of Substance Abuse
177(1)
6.1.2 Glossary of Terms
178(2)
6.2 Brief Description and Diagnostic Criteria
180(3)
6.3 Prevalence and Risk Factors
183(1)
6.4 Presentation and Clinical Course
184(2)
6.5 Initial Evaluation and Differential Diagnosis
186(2)
6.6 History of Treatment
188(2)
6.7 Current Approaches to Treatment
190(2)
6.8 Alcohol Use Disorders
192(6)
6.8.1 History of Treatment
192(5)
6.8.2 Current Approach to Treatment
197(1)
6.9 Cocaine Use Disorders
198(2)
6.9.1 History of Treatment
198(1)
6.9.2 Current Approach to Treatment
199(1)
6.10 Nicotine Dependence
200(1)
6.10.1 History of Treatment
200(1)
6.10.2 Current Approach to Treatment
201(1)
6.11 Opiate Use Disorders
201(5)
6.11.1 History of Treatment
201(4)
6.11.2 Current Approach to Treatment
205(1)
Additional Reading
206(1)
7 EATING DISORDERS
207(24)
7.1 Introduction
207(2)
7.2 Anorexia Nervosa
209(8)
7.2.1 Brief Description and Diagnostic Criteria
209(1)
7.2.2 Prevalence and Risk Factors
210(1)
7.2.3 Presentation and Clinical Course
211(1)
7.2.4 Initial Evaluation and Differential Diagnosis
211(2)
7.2.5 History of Pharmacological Treatment
213(3)
7.2.6 Current Approach to Treatment
216(1)
7.3 Bulimia Nervosa
217(7)
7.3.1 Brief Description and Diagnostic Criteria
217(1)
7.3.2 Prevalence and Risk Factors
218(1)
7.3.3 Presentation and Clinical Course
219(1)
7.3.4 Initial Evaluation and Differential Diagnosis
220(1)
7.3.5 History of Pharmacological Treatment
221(1)
7.3.6 Current Approach to Treatment
222(1)
7.3.7 Patients with Refractory Disease
223(1)
7.4 Binge-Eating Disorder
224(5)
7.4.1 Brief Description and Diagnostic Criteria
224(1)
7.4.2 Prevalence and Risk Factors
225(1)
7.4.3 Presentation and Clinical Course
225(1)
7.4.4 Initial Evaluation and Differential Diagnosis
225(1)
7.4.5 History of Pharmacological Treatment
226(2)
7.4.6 Current Approach to Treatment
228(1)
Additional Reading
229(2)
8 ATTENTION DEFICIT–HYPERACTIVITY DISORDER
231(26)
8.1 Brief Description and Diagnostic Criteria
231(2)
8.2 Prevalence and Risk Factors
233(2)
8.3 Presentation and Clinical Course
235(1)
8.4 Initial Evaluation and Differential Diagnosis
236(3)
8.5 History of Pharmacological Treatment
239(10)
8.6 Current Approach to Treatment
249(6)
Additional Reading
255(2)
9 SLEEP DISORDERS
257(26)
9.1 Introduction
257(3)
9.1.1 Normal Sleep
258(1)
9.1.2 Overview of Sleep Disorders
259(1)
9.2 Insomnia
260(15)
9.2.1 Brief Description and Diagnostic Criteria
260(1)
9.2.2 Prevalence and Risk Factors
261(1)
9.2.3 Presentation and Clinical Course
262(1)
9.2.4 Initial Evaluation and Differential Diagnosis
262(4)
9.2.5 History of Pharmacological Treatment
266(7)
9.2.6 Current Approach to Treatment
273(2)
9.3 Narcolepsy
275(6)
9.3.1 Brief Description and Diagnostic Criteria
275(1)
9.3.2 Prevalence and Risk Factors
276(1)
9.3.3 Presentation and Clinical Course
276(1)
9.3.4 Initial Evaluation and Differential Diagnosis
277(1)
9.3.5 History of Pharmacological Treatment
277(3)
9.3.6 Current Approach to Treatment
280(1)
Additional Reading
281(2)
10 ALZHEIMER'S DISEASE AND OTHER DEMENTIAS 283(30)
10.1 Brief Description and Diagnostic Criteria
283(2)
10.2 Prevalence and Risk Factors
285(3)
10.2.1 Causes of Dementia
286(1)
10.2.2 Risk Factors for Dementia
287(1)
10.3 Presentation and Clinical Course
288(1)
10.4 Initial Evaluation and Differential Diagnosis
289(4)
10.4.1 Initial Evaluation
289(1)
10.4.2 Differential Diagnosis
290(3)
10.5 History of Pharmacological Treatment
293(10)
10.5.1 Overview and Current Theory
293(1)
10.5.2 Historical Treatment Strategies
294(1)
10.5.3 History of Dementia Reversal Treatments
295(1)
10.5.4 History of Brain Protection Treatments
296(1)
10.5.5 History of Cognitive Enhancement Treatments
297(4)
10.5.6 History of Behavioral Management Treatments
301(2)
10.6 Current Approach to Treatment
303(7)
10.6.1 Current Treatment Options at Different Stages of Dementia
304(1)
10.6.2 Current Options for Cognitive Enhancement
305(1)
10.6.3 Current Options for Brain Protection
305(1)
10.6.4 Current Options for Treatment of Behavioral and Emotional Problems
306(4)
Additional Reading
310(3)
11 PERSONALITY DISORDERS 313(24)
11.1 Introduction
313(4)
11.1.1 How Little We Know
313(2)
11.1.2 Defining a Personality Disorder
315(1)
11.1.3 Prerequisites to Beginning Treatment
316(1)
11.2 Cluster A: Odd and Eccentric Personality Disorders
317(5)
11.2.1 Brief Description and Diagnostic Criteria
317(1)
11.2.2 Prevalence and Risk Factors
318(1)
11.2.3 Initial Evaluation and Differential Diagnosis
318(2)
11.2.4 History of Pharmacological Treatment
320(1)
11.2.5 Current Approach to Treatment
321(1)
11.3 Cluster B: Dramatic and Emotional Personality Disorders
322(9)
11.3.1 Brief Description and Diagnostic Criteria
322(1)
11.3.2 Prevalence and Risk Factors
323(1)
11.3.3 Initial Evaluation and Differential Diagnosis
324(2)
11.3.4 History of Pharmacological Treatment
326(3)
11.3.5 Current Approach to Treatment
329(2)
11.4 Cluster C: Anxious and Fearful Personality Disorders
331(4)
11.4.1 Brief Description and Diagnostic Criteria
331(1)
11.4.2 Prevalence and Risk Factors
332(1)
11.4.3 Initial Evaluation and Differential Diagnosis
332(1)
11.4.4 History of Pharmacological Treatment
333(2)
11.4.5 Current Approach to Treatment
335(1)
Additional Reading
335(2)
12 TRAUMATIC BRAIN INJURY 337(16)
12.1 Introduction
337(4)
12.1.1 Brief Description and Diagnostic Criteria
337(1)
12.1.2 Prevalence and Risk Factors
337(1)
12.1.3 Presentation and Clinical Course
338(2)
12.1.4 Initial Evaluation and Differential Diagnosis
340(1)
12.2 Approaches to Treatment
341(11)
12.2.1 Post-TBI Depression
341(1)
12.2.2 Post-TBI Apathy
342(2)
12.2.3 Post-TBI Mania
344(2)
12.2.4 Post-TBI Psychosis
346(1)
12.2.5 Post-TBI Anxiety
347(1)
12.2.6 Post-TBI Dementia and Delirium
348(1)
12.2.7 Post-TBI Behavioral Disturbances
349(3)
Additional Reading
352(1)
13 MANAGING SIDE EFFECTS 353(30)
13.1 Introduction
353(7)
13.1.1 Organizing This Discussion
353(2)
13.1.2 Recognizing Side Effects
355(3)
13.1.3 General Approach to Managing Side Effects
358(2)
13.2 Norepinephrine-Related Side Effects
360(3)
13.2.1 Side Effects of Norepinephrine-Boosting Medications
360(2)
13.2.2 Side Effects of Norepinephrine-Blocking Medications
362(1)
13.3 Dopamine-Related Side Effects
363(8)
13.3.1 Side Effects of Dopamine-Boosting Medications
363(2)
13.3.2 Side Effects of Dopamine-Blocking Medications
365(6)
13.4 Serotonin-Related Side Effects
371(5)
13.4.1 Side Effects of Serotonin-Boosting Medications
371(4)
13.4.2 Side Effects of Serotonin-Blocking Medications
375(1)
13.5 GABA-Related Side Effects
376(1)
13.5.1 Side Effects of GABA Boosting Medications
376(1)
13.5.2 Side Effects of GABA-Blocking Medications
377(1)
13.6 Acetylcholine-Related Side Effects
377(2)
13.6.1 Side Effects of Acetylcholine-Boosting Medications
377(1)
13.6.2 Side Effects of Acetylcholine-Blocking Medications
378(1)
13.7 Histamine-Related Side Effects
379(4)
13.7.1 Side Effects of Histamine-Blocking Medications
379(4)
Index 383

Supplemental Materials

What is included with this book?

The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.

The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.

Rewards Program